Analysis of glioblastoma multiforme and normal brain tissue

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study conducts an integrative analysis of glioblastoma multiforme (GBM) by examining the proteomes of paired normal brain tissues and GBM. It involves sequencing transcriptomes, performing whole exome sequencing, and conducting single nucleotide polymorphism (SNP) array profiling on samples that include normal brain tissue, primary GBM carcinoma, and its synchronous matched metastasis. Additionally, it analyzes genomic data from GBM previously characterized by The Cancer Genome Atlas (TCGA) to facilitate integrated proteogenomic analyses.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≤ 75 years with histologically proven GBM
* No severe major organ dysfunction
* World Health Organization (WHO) performance status of 0 or 1
* No prior cancer chemotherapy

Exclusion Criteria:

* Age ≥ 76
* Severe major organ dysfunction
* WHO performance status of \>1
* Prior cancer chemotherapy

Where it's running

• Shanghai Tenth People's Hospital
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Principal investigator: Da Fu, PhD — Shanghai 10th People's Hospital
• Study coordinator: Da Fu, PhD
• Email: fu800da900@126.com
• Phone: 00-86-21-66301604

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Butterfly glioblastoma: test adding 5-ALA PoMA with LIDU ultrasound to standard care

  This early-phase study tests whether adding 5-ALA–mediated activation with LIDU ultrasound is safe and tolerable for adults with newly diagnosed butterfly glioblastoma, before or during standard chemotherapy and radiotherapy.

  Recruiting Phase 1 Alpheus Medical, Inc. · Buffalo, New York · NCT07862647

• LMP744 (an indenoisoquinolone) for people with recurrent glioblastoma

  This trial will test whether the drug LMP744 can shrink tumors or slow progression in adults whose glioblastoma has returned after prior treatment.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07416188

• How Acetadote might affect metabolism in newly diagnosed glioblastoma

  This early-phase trial tests whether Acetadote can change brain tumor metabolism in adults with a new glioblastoma diagnosis.

  Recruiting Early Phase 1 University of Texas Southwestern Medical Center · Dallas, Texas · NCT07387666

• Surgery and Laser Therapy for Bilateral Glioblastoma

  This study tests surgery and laser-induced thermal therapy to treat bilateral glioblastoma in people whose tumors cross both brain hemispheres.

  Recruiting King's College Hospital NHS Trust · London · NCT07384884

• Silevertinib plus temozolomide for newly diagnosed GBM with unmethylated MGMT and EGFRvIII

  This trial tests whether adding silevertinib to standard temozolomide helps people with newly diagnosed glioblastoma that have EGFRvIII and an unmethylated MGMT promoter live longer without the cancer getting worse.

  Recruiting at 38 sites Phase 2 Black Diamond Therapeutics, Inc. · Birmingham, Alabama and 37 other locations · NCT07326566

• Standard temozolomide plus 5‑ALA and low‑intensity ultrasound after surgery for newly diagnosed glioblastoma

  This trial tests whether adding the light‑activated drug 5‑ALA together with a low‑intensity ultrasound device to standard temozolomide can help people with newly diagnosed glioblastoma after surgery and chemoradiation.

  Recruiting at 11 sites Phase 2 Alpheus Medical, Inc. · Boston, Massachusetts and 10 other locations · NCT07225621

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.